Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Marcia S. Brose(University of Pennsylvania), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Ezra E.W. Cohen(University of California, San Diego), Lori J. Wirth(Massachusetts General Hospital), Todd Riehl, Huibin Yue, Steven I. Sherman(The University of Texas MD Anderson Cancer Center), Eric J. Sherman(Memorial Sloan Kettering Cancer Center)
The Lancet Oncology
July 23, 2016
10.1016/s1470-2045(16)30166-8
Cited by 383Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis